Publication Name	World Journal of Clinical Oncology
Manuscript ID	33517
Country	Italy

Category	Oncology
Manuscript Type	Minireviews
Article Title	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
Manuscript Source	Invited Manuscript
All Author List	Carmelo Tibaldi, Alice Lunghi and Editta Baldini
Funding Agency and Grant Number
Corresponding Author	Dr. Carmelo Tibaldi, Division of Oncology, Department of Oncology, S. Luca Hospital, Via Guglielmo Lippi Francesconi 1, 55100 Lucca, Italy. carmelo.tibaldi@uslnordovest.toscana.it
Key Words	Predictive biomarkers; Immunotherapy; Checkpoint inhibitors; Programmed cell death protein ligand 1; Non-small cell lung cancer
Core Tip	Use of programmed cell death protein ligand 1 (PD-L1) assay to predict the outcomes of non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors. This minireview underlines promises and pitfalls of the PD-L1 expression to predict the activity and efficacy of programmed cell death protein 1/PD-L1 inhibitors in NSCLC.
Citation	Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328

Received	2017-02-14 08:56
Peer-Review Started	2017-02-14 17:43
To Make the First Decision	2017-04-14 10:31
Return for Revision	2017-04-19 15:11
Revised	2017-05-13 03:49
Second Decision	2017-05-16 02:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2017-05-24 00:47
Articles in Press	2017-05-24 00:47
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-08-03 03:48

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com